Evidence map›Paper›PMID 29348535›Full record

ArticleScientific reports2018

Umbilical cord extracts improve osteoporotic abnormalities of bone marrow-derived mesenchymal stem cells and promote their therapeutic effects on ovariectomised rats.

Akira Saito, Kanna Nagaishi, Kousuke Iba, Yuka Mizue, Takako Chikenji, Miho Otani, Masako Nakano, Kazusa Oyama, Toshihiko Yamashita, Mineko Fujimiya

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Use of Human Umbilical Cord and Its Byproducts in Tissue Regeneration.Frontiers in bioengineering and biotechnology · 2020
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Akira SaitoDepartment of Orthopaedic Surgery, Sapporo Medical University, Sapporo, Japan.
Kanna NagaishiSecond Department of Anatomy, Sapporo Medical University, Sapporo, Japan. kanna@sapmed.ac.jp.
Kousuke IbaDepartment of Orthopaedic Surgery, Sapporo Medical University, Sapporo, Japan.
Yuka MizueSecond Department of Anatomy, Sapporo Medical University, Sapporo, Japan.
Takako ChikenjiSecond Department of Anatomy, Sapporo Medical University, Sapporo, Japan.ORCID http://orcid.org/0000-0003-2832-3656
Miho OtaniDepartment of Diabetic Cellular Therapeutics, Sapporo Medical University, Sapporo, Japan.
Masako NakanoSecond Department of Anatomy, Sapporo Medical University, Sapporo, Japan.
Kazusa OyamaSecond Department of Anatomy, Sapporo Medical University, Sapporo, Japan.
Toshihiko YamashitaDepartment of Orthopaedic Surgery, Sapporo Medical University, Sapporo, Japan.
Mineko FujimiyaSecond Department of Anatomy, Sapporo Medical University, Sapporo, Japan.
Sapporo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone marrow-derived mesenchymal stem cells (BM-MSCs) are the most valuable source of autologous cells for transplantation and tissue regeneration to treat osteoporosis. Although BM-MSCs are the primary cells responsible for maintaining bone metabolism and homeostasis, their regenerative ability may be attenuated in postmenopausal osteoporosis patients. Therefore, we first examined potential abnormalities of BM-MSCs in an oestrogen-deficient rat model constructed by ovariectomy (OVX-MSCs). Cell proliferation, mobilisation, and regulation of osteoclasts were downregulated in OVX-MSCs. Moreover, therapeutic effects of OVX-MSCs were decreased in OVX rats. Accordingly, we developed a new activator for BM-MSCs using human umbilical cord extracts, Wharton's jelly extract supernatant (WJS), which improved cell proliferation, mobilisation and suppressive effects on activated osteoclasts in OVX-MSCs. Bone volume, RANK and TRACP expression of osteoclasts, as well as proinflammatory cytokine expression in bone tissues, were ameliorated by OVX-MSCs activated with WJS (OVX-MSCs-WJ) in OVX rats. Fusion and bone resorption activity of osteoclasts were suppressed in macrophage-induced and primary mouse bone marrow cell-induced osteoclasts via suppression of osteoclast-specific genes, such as Nfatc1, Clcn7, Atp6i and Dc-stamp, by co-culture with OVX-MSCs-WJ in vitro. In this study, we developed a new activator, WJS, which improved the functional abnormalities and therapeutic effects of BM-MSCs on postmenopausal osteoporosis.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsBiomarkersBone DensityBone Marrow CellsChloride ChannelsCoculture TechniquesComplex MixturesDisease Models, AnimalFemaleGene ExpressionMesenchymal Stem CellsMiceOsteoclastsOsteoporosisOvariectomyBiomarkersChloride ChannelsClcn7 protein, ratComplex MixturesNFATC1 protein, ratReceptor Activator of Nuclear Factor-kappa BTartrate-Resistant Acid PhosphataseTranscription Factors

Identifiers

PMID29348535
PMCPMC5773568
OpenAlexW2782553270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.